Literature DB >> 24928363

From the cell of Schwann to schwannoma--a century's fruition.

Ashish Sonig1, Viraj Gandhi2, Anil Nanda3.   

Abstract

The word "schwannoma" is pervasive throughout the neurosurgical community. However, little is known about the origin of the cell of "Schwann cell," the manifestation of the tumor's nomenclature, or the prominent physicians who studied its etiopathogenesis. Schwann was a founding father of cellular theory and one of the greatest scientists of the 19th century. He not only proposed cell theory but also discovered the "secondary" nerve cell and hypothesized its possible function in myelination. It took a century to confirm Schwann's hypothesis. In 1954, Geren, aided by the electron microscope, demonstrated that the cell of Schwann is responsible for nerve myelination. Concurrently, researchers worked to understand the etiology and pathogenesis of peripheral nerve neoplasms. Several attempts were made; Older, Virchow, and von Recklinghausen were the first pioneers who worked on the classification of these neoplasms. However, Masson first used the word "schwannoma" to describe peripheral nerve neoplasms other than neuromas. His French colleague Nageotte used the term "peripheral-glioma" to denote these tumors. These schwannomas were considered to have a malignant course. In 1932, Penfield attempted to classify peripheral nerve neoplasms into 3 categories: peripheral fibroblastoma, peripheral glioma, and neurofibroma of von Recklinghausen. He classified "Verocay's neurinoma," "Masson's schwannoma," and "cerebellopontine angle" tumors as perineural fibroblastoma. He believed that these tumors have a non-nerve cell, non-Schwann cell origin. He classified the tumors arising from the Schwann cell sheath as peripheral gliomas and articulated, "If any tumors are to be called schwannomas, these should be." The neurofibroma of von Recklinghausen was recognized as a separate entity, as described by von Recklinghausen himself. Murray and Stout proposed that schwannomas are essentially benign in nature clarifying the abstruseness of the benign or malignant nature of schwannoma.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell of Schwann; Schwann; Schwannoma; Theodor Ambrose Hubert Schwann; Vestibular schwannoma

Mesh:

Year:  2014        PMID: 24928363     DOI: 10.1016/j.wneu.2014.05.038

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Radiation risk of central nervous system tumors in the Life Span Study of atomic bomb survivors, 1958-2009.

Authors:  Alina V Brenner; Hiromi Sugiyama; Dale L Preston; Ritsu Sakata; Benjamin French; Atsuko Sadakane; Elizabeth K Cahoon; Mai Utada; Kiyohiko Mabuchi; Kotaro Ozasa
Journal:  Eur J Epidemiol       Date:  2020-01-25       Impact factor: 8.082

2.  Rediagnosing one of Smith's patients (John McCann) with "neuromas tumours" (1849).

Authors:  Martino Ruggieri; Andrea D Praticò; Rosario Caltabiano; Agata Polizzi
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

3.  Early history of neurofibromatosis type 2 and related forms: earliest descriptions of acoustic neuromas, medical curiosities, misconceptions, landmarks and the pioneers behind the eponyms.

Authors:  Martino Ruggieri; Andrea D Praticò; Agostino Serra; Luigi Maiolino; Salvatore Cocuzza; Rosario Caltabiano; Agata Polizzi
Journal:  Childs Nerv Syst       Date:  2016-09-26       Impact factor: 1.475

4.  A reciprocal regulatory loop between TAZ/YAP and G-protein Gαs regulates Schwann cell proliferation and myelination.

Authors:  Yaqi Deng; Lai Man Natalie Wu; Shujun Bai; Chuntao Zhao; Haibo Wang; Jincheng Wang; Lingli Xu; Masahide Sakabe; Wenhao Zhou; Mei Xin; Q Richard Lu
Journal:  Nat Commun       Date:  2017-04-26       Impact factor: 14.919

5.  Partially intraosseous schwannoma of the distal humerus with increased enhancement after biopsy: Radiologic-pathologic correlation.

Authors:  Shan S Hansra; Colin N Brown; Lisa H Kang; Kurt B Schaberg; Steven W Thorpe; Dillon C Chen
Journal:  Radiol Case Rep       Date:  2022-02-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.